Risk of breast cancer in relation to use of combined oral contraceptives near the age of menopause

1991 ◽  
Vol 2 (6) ◽  
pp. 389-394 ◽  
Author(s):  
David B. Thomas ◽  
Elizabeth A. Noonan ◽  
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptives ◽  
Combined Oral Contraceptives

Breast cancer and combined oral contraceptives: An Italian case-control study

1989 ◽  
Vol 25 (11) ◽  
pp. 1613-1618 ◽  
Author(s):  
Carlo La Vecchia ◽  
Fabio Parazzini ◽  
Eva Negri ◽  
Peter Boyle ◽  
Antonella Gentile ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptives ◽  
Case Control Study ◽  
Case Control ◽  
Combined Oral Contraceptives ◽  
Italian Case ◽  
Control Study

scholarly journals Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: The Norwegian Women and Cancer Study

2018 ◽  
Vol 142 (11) ◽  
pp. 2293-2302 ◽  
Author(s):  
Marit Busund ◽  
Nora S. Bugge ◽  
Tonje Braaten ◽  
Marit Waaseth ◽  
Charlotta Rylander ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Oral Contraceptives ◽  
Premenopausal Breast Cancer ◽  
Combined Oral Contraceptives ◽  
Cancer Study

Benefits and Risks of Combined Oral Contraceptives

1993 ◽  
Vol 32 (03) ◽  
pp. 222-224 ◽  
Author(s):  
M. P. Vessey
Keyword(s):  
Breast Cancer ◽  
Myocardial Infarction ◽  
Adverse Effect ◽  
Acute Myocardial Infarction ◽  
Oral Contraceptives ◽  
Haemorrhagic Stroke ◽  
Protective Effects ◽  
Epithelial Cancer ◽  
Combined Oral Contraceptives ◽  
Number Of Authors

Abstract:The use of combined oral contraceptives carries a number of well-established major non-contraceptive benefits. Of these, the most important protective effects are suppression of the risk of epithelial cancer of the ovary and cancer of the endometrium. Also of great importance is a reduction in the risk of pelvic inflammatory disease. Needless to say, there are also some established risks of combined oral contraceptives. The most important of these are the vascular ones, comprising effects on acute myocardial infarction, thrombotic stroke, haemorrhagic stroke, and venous thrombosis and embolism. Possible risks which are still under evaluation include an adverse effect on breast cancer and, likewise, on carcinoma of the cervix. More information is needed about both these conditions. A number of authors have provided analyses of varying degrees of complexity in which they have attempted to weigh the benefits and risks of combined oral contraceptives. Results from some of these studies are presented in the paper. On the whole, the findings are reasonably reassuring.

Platelet Adhesiveness in Symptomatic Women Taking Oral Contraceptives

1971 ◽  
Vol 26 (03) ◽  
pp. 426-430 ◽  
Author(s):  
T. F Zuck ◽  
J. J Bergin ◽  
Jane M. Raymond ◽  
W. R Dwyre ◽  
D. G Corby
Keyword(s):  
Oral Contraceptives ◽  
Platelet Adhesiveness ◽  
Combined Oral Contraceptives ◽  
Increased Risk ◽  
Normal Women ◽  
Asymptomatic Women

SummaryPlatelet adhesiveness to glass was determined in several groups of women. Increases were found in women developing thrombovascular symptoms while taking combined oral contraceptives, compared to both normal women and asymptomatic users of oral contraceptives. Despite this increase, overlap of the groups did not permit discrimination between symptomatic and asymptomatic women. However, it is possible, that in concert with other coagulation changes, platelet adhesiveness to glass may prove adjunctive in defining women at increased risk of developing thrombovascular symptoms while taking oral contraceptives, and further define the mechanism of the increased risk.

Sign in / Sign up

Export Citation Format

Share Document